253124-22-0

Upstream product

• 253124-20-8 6-[(2S,5R)-2,6-Bis-tert-butoxycarbonylamino-5-((2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yloxy)-hexanoylamino]-hexanoic acid 2,5-dioxo-pyrrolidin-1-yl ester 
• 24424-99-5 di-tert-butyl dicarbonate 
• 2219-28-5 (R)-5-hydroxy-L-lysine dihydrochloride hydrate 
• 253124-16-2 (-)-tert-butyl-(3S,6R)-6-{[(tert-butoxycarbonyl)amino]methyl}-2-oxotetrahydro-2H-pyran-3-ylcarbamate 
• 253124-17-3 (-)-methyl 6-({(2S,5R)-2,6-bis[(tert-butoxycarbonyl)amino]-5-hydroxyhexanoyl}amino)hexanoate 
• 253124-19-5 6-[(2S,5R)-2,6-Bis-tert-butoxycarbonylamino-5-((2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yloxy)-hexanoylamino]-hexanoic acid 
• 253124-18-4 6-[(2S,5R)-2,6-Bis-tert-butoxycarbonylamino-5-((2R,3R,4S,5S,6R)-3,4,5-triacetoxy-6-acetoxymethyl-tetrahydro-pyran-2-yloxy)-hexanoylamino]-hexanoic acid methyl ester 

Relevant academic research and scientific papers

Synthesis of immunoreagents for measurement of galactosylhydroxylysine

(2S,5R)-(+)-Hydroxylysine (6) was transformed into (-)-succinimidyl ester (13) and conjugated to BSA or KLH to form immunogens (2 and 3) for generation of anti-galactosylhydroxylysine antibodies. Additionally, treatment of (-)-13 with 6-Fln-CH2